1,026 reports of this reaction
3.2% of all MECLIZINE HCL 12.5 MG reports
#3 most reported adverse reaction
FATIGUE is the #3 most commonly reported adverse reaction for MECLIZINE HCL 12.5 MG, manufactured by Advanced Rx LLC. There are 1,026 FDA adverse event reports linking MECLIZINE HCL 12.5 MG to FATIGUE. This represents approximately 3.2% of all 32,440 adverse event reports for this drug.
Patients taking MECLIZINE HCL 12.5 MG who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among MECLIZINE HCL 12.5 MG users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for MECLIZINE HCL 12.5 MG:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 1,026 FDA reports for MECLIZINE HCL 12.5 MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.2% of all adverse event reports for MECLIZINE HCL 12.5 MG, making it one of the most commonly reported side effect.
If you experience fatigue while taking MECLIZINE HCL 12.5 MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.